209 related articles for article (PubMed ID: 29440297)
21. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Ogitani Y; Aida T; Hagihara K; Yamaguchi J; Ishii C; Harada N; Soma M; Okamoto H; Oitate M; Arakawa S; Hirai T; Atsumi R; Nakada T; Hayakawa I; Abe Y; Agatsuma T
Clin Cancer Res; 2016 Oct; 22(20):5097-5108. PubMed ID: 27026201
[TBL] [Abstract][Full Text] [Related]
22. ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.
Smith RA; Zammit DJ; Damle NK; Usansky H; Reddy SP; Lin JH; Mistry M; Rao NS; Denis LJ; Gupta S
Mol Cancer Ther; 2021 Aug; 20(8):1327-1337. PubMed ID: 34045226
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of theranostic Trastuzumab-SN38 conjugate for Near-IR fluorescence imaging and targeted therapy of HER2+ breast cancer.
Kobzev D; Prasad C; Walunj D; Gotman H; Semenova O; Bazylevich A; Patsenker L; Gellerman G
Eur J Med Chem; 2023 Apr; 252():115298. PubMed ID: 36966651
[TBL] [Abstract][Full Text] [Related]
24. A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab.
Sijbrandi NJ; Merkul E; Muns JA; Waalboer DC; Adamzek K; Bolijn M; Montserrat V; Somsen GW; Haselberg R; Steverink PJ; Houthoff HJ; van Dongen GA
Cancer Res; 2017 Jan; 77(2):257-267. PubMed ID: 27872093
[TBL] [Abstract][Full Text] [Related]
25. [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
Takegawa N; Tsurutani J; Kawakami H; Yonesaka K; Kato R; Haratani K; Hayashi H; Takeda M; Nonagase Y; Maenishi O; Nakagawa K
Int J Cancer; 2019 Dec; 145(12):3414-3424. PubMed ID: 31087550
[TBL] [Abstract][Full Text] [Related]
26. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.
Loganzo F; Tan X; Sung M; Jin G; Myers JS; Melamud E; Wang F; Diesl V; Follettie MT; Musto S; Lam MH; Hu W; Charati MB; Khandke K; Kim KS; Cinque M; Lucas J; Graziani E; Maderna A; O'Donnell CJ; Arndt KT; Gerber HP
Mol Cancer Ther; 2015 Apr; 14(4):952-63. PubMed ID: 25646013
[TBL] [Abstract][Full Text] [Related]
27. Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs.
Andreev J; Thambi N; Perez Bay AE; Delfino F; Martin J; Kelly MP; Kirshner JR; Rafique A; Kunz A; Nittoli T; MacDonald D; Daly C; Olson W; Thurston G
Mol Cancer Ther; 2017 Apr; 16(4):681-693. PubMed ID: 28108597
[TBL] [Abstract][Full Text] [Related]
28. A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
Iwata TN; Ishii C; Ishida S; Ogitani Y; Wada T; Agatsuma T
Mol Cancer Ther; 2018 Jul; 17(7):1494-1503. PubMed ID: 29703841
[TBL] [Abstract][Full Text] [Related]
29. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.
Erickson HK; Lewis Phillips GD; Leipold DD; Provenzano CA; Mai E; Johnson HA; Gunter B; Audette CA; Gupta M; Pinkas J; Tibbitts J
Mol Cancer Ther; 2012 May; 11(5):1133-42. PubMed ID: 22408268
[TBL] [Abstract][Full Text] [Related]
30. Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity.
Ríos-Luci C; García-Alonso S; Díaz-Rodríguez E; Nadal-Serrano M; Arribas J; Ocaña A; Pandiella A
Cancer Res; 2017 Sep; 77(17):4639-4651. PubMed ID: 28687619
[TBL] [Abstract][Full Text] [Related]
31. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
[TBL] [Abstract][Full Text] [Related]
32. Novel Thienoduocarmycin-Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies.
Valsasina B; Orsini P; Caruso M; Albanese C; Ciavolella A; Cucchi U; Fraietta I; Melillo N; Fiorentini F; Rizzi S; Salsa M; Isacchi A; Gasparri F
Mol Cancer Ther; 2023 Dec; 22(12):1465-1478. PubMed ID: 37722716
[TBL] [Abstract][Full Text] [Related]
33. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads.
Nakada T; Masuda T; Naito H; Yoshida M; Ashida S; Morita K; Miyazaki H; Kasuya Y; Ogitani Y; Yamaguchi J; Abe Y; Honda T
Bioorg Med Chem Lett; 2016 Mar; 26(6):1542-1545. PubMed ID: 26898815
[TBL] [Abstract][Full Text] [Related]
34. [Pharmacological effects of site specific conjugated anti-human epidermal growth factor receptor 2-antibody drug conjugate using unnatural amino acid technology].
Liang XJ; Gong LY; Zhou F; Zhou DM; Zhu JJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 51(5):797-804. PubMed ID: 31624380
[TBL] [Abstract][Full Text] [Related]
35. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells.
Singh R; Setiady YY; Ponte J; Kovtun YV; Lai KC; Hong EE; Fishkin N; Dong L; Jones GE; Coccia JA; Lanieri L; Veale K; Costoplus JA; Skaletskaya A; Gabriel R; Salomon P; Wu R; Qiu Q; Erickson HK; Lambert JM; Chari RV; Widdison WC
Mol Cancer Ther; 2016 Jun; 15(6):1311-20. PubMed ID: 27197308
[TBL] [Abstract][Full Text] [Related]
36. Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer.
Hayashi T; Seiler R; Oo HZ; Jäger W; Moskalev I; Awrey S; Dejima T; Todenhöfer T; Li N; Fazli L; Matsubara A; Black PC
J Urol; 2015 Oct; 194(4):1120-31. PubMed ID: 26047983
[TBL] [Abstract][Full Text] [Related]
37. Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance.
Dillon RL; Chooniedass S; Premsukh A; Adams GP; Entwistle J; MacDonald GC; Cizeau J
J Immunother; 2016 Apr; 39(3):117-26. PubMed ID: 26938945
[TBL] [Abstract][Full Text] [Related]
38. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
Phillips AC; Boghaert ER; Vaidya KS; Falls HD; Mitten MJ; DeVries PJ; Benatuil L; Hsieh CM; Meulbroek JA; Panchal SC; Buchanan FG; Durbin KR; Voorbach MJ; Reuter DR; Mudd SR; Loberg LI; Ralston SL; Cao D; Gan HK; Scott AM; Reilly EB
Mol Cancer Ther; 2018 Apr; 17(4):795-805. PubMed ID: 29483208
[TBL] [Abstract][Full Text] [Related]
39. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.
Nicoletti R; Lopez S; Bellone S; Cocco E; Schwab CL; Black JD; Centritto F; Zhu L; Bonazzoli E; Buza N; Hui P; Mezzanzanica D; Canevari S; Schwartz PE; Rutherford TJ; Santin AD
Clin Exp Metastasis; 2015 Jan; 32(1):29-38. PubMed ID: 25398397
[TBL] [Abstract][Full Text] [Related]
40. A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine.
Le Joncour V; Martins A; Puhka M; Isola J; Salmikangas M; Laakkonen P; Joensuu H; Barok M
Mol Cancer Ther; 2019 Oct; 18(10):1721-1730. PubMed ID: 31292166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
